Immunovant (NASDAQ:IMVT) versus CG Oncology (NASDAQ:CGON) Critical Comparison

Immunovant (NASDAQ:IMVT) and CG Oncology (NASDAQ:CGON) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Institutional and Insider Ownership

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Immunovant and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
CG Oncology	N/A	-23.33%	-22.24%

Analyst Recommendations

This is a breakdown of current ratings for Immunovant and CG Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1	4	6	0	2.45
CG Oncology	1	2	11	0	2.71

Immunovant presently has a consensus target price of $39.70, indicating a potential downside of 1.51%. CG Oncology has a consensus target price of $81.73, indicating a potential upside of 17.09%. Given CG Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Immunovant.

Volatility & Risk

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

Earnings & Valuation

This table compares Immunovant and CG Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61 million	($2.78)	-14.50
CG Oncology	$4.04 million	1,523.85	-$160.99 million	($2.33)	-29.96

CG Oncology has higher revenue and earnings than Immunovant. CG Oncology is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Summary

CG Oncology beats Immunovant on 9 of the 12 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.